CRISPR Therapeutics reported dose-dependent, durable reductions in circulating ANGPTL3 and key lipids following a single intravenous infusion of CTX310. At the highest dose cohort, patients achieved mean reductions of 73% in ANGPTL3 (peak 89%), 55% in triglycerides (peak 84%) and 49% in LDL cholesterol (peak 87%). In the subgroup with baseline triglycerides above 150 mg/dL, mean reductions reached 60% at therapeutic dose levels. No treatment-related serious adverse events were observed, and there were no Grade 3 or higher liver transaminase elevations, underlining a clean safety profile that supports advancement into Phase 1b studies targeting severe hypertriglyceridemia and mixed dyslipidemia.

CRISPR Therapeutics currently commands a market capitalization near $5 billion, anchored by the recent commercial approval of its SCD and TDT therapy, Casgevy, and the transformative clinical data presented in pediatric sickle cell and beta-thalassemia studies. Although the initial commercial ramp for Casgevy in children has been modest, management expects patient uptake and revenue to accelerate over 2026 as global regulatory filings commence in the first half of the year, bolstered by receipt of a Priority Review Voucher that could shorten review timelines to as little as one to two months.

Beyond CTX310 and Casgevy, CRISPR Therapeutics’ pipeline spans in vivo gene-editing candidates, CAR-T cell therapies and diabetes-focused assets. The cardiovascular program targeting ANGPTL3 is now moving into Phase 1b, while preclinical data for an in vivo diabetes candidate have demonstrated durable restoration of endogenous insulin production in animal models. Additionally, the company is advancing at least two CAR-T constructs against solid-tumor antigens with IND-enabling studies scheduled for late 2026. This breadth of programs provides multiple de-risking catalysts and potential value inflection points over the next two to three years.